ImClone Closing Branchburg, New Jersey Manufacturing Facility
08/17/2010
"This decision was made after careful consideration of a number of internal and external factors related to Erbitux [a cancer drug]," said Janice Chavers, an Eli Lilly spokesperson. "The decision was not driven by Lilly's larger restructuring effort."
ImClone currently has 90 open positions for which employees affected by the layoffs will have priority. The closure plans are effective immediately.
Project Announcements
Australia-Based Aquatic Leisure Technologies Group Plans Opp, Alabama, Manufacturing Operations
12/11/2025
Teradyne Plans Wixom, Michigan, Robotics Operations
12/11/2025
Robinson Plans Altoona, Iowa, Manufacturing Operations
12/11/2025
BioTouch Expands Columbus, Georgia, Operations
12/11/2025
Natrion Plans Erie County, New York, Battery Components Operations
12/11/2025
Czech-Based GZ PrintPak Expands Mount Pleasant, Wisconsin, Manufacturing Operations
12/11/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025